华蟾素对晚期非小细胞肺癌患者证候及血清肿瘤标志物、免疫功能的影响  

The Influence of Cinobufacin on the Improvement of Syndromes,Serum Tumor Markers and Immune Function in Patients with Advanced Non-small Cell Lung Cancer

作　　者：李铭一 吴静[1] 尹元 栾宝鑫 LI Mingyi;WU Jing;YIN Yuan;LUAN Baoxin(Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;Shanghai TCM-integrated Hospital,Shanghai University of TCM,Shanghai 200082,China;Obstetrics and Gynecology Hospital of Fudan University,Shanghai 200090,China)

机构地区：[1]上海交通大学医学院附属新华医院,上海200092 [2]上海市中西医结合医院,上海200082 [3]复旦大学附属妇产科医院,上海200090

出　　处：《西部中医药》2024年第5期139-142,共4页Western Journal of Traditional Chinese Medicine

基　　金：上海市卫健委青年科研项目(20174Y0016)。

摘　　要：目的:探讨华蟾素对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的中医证候及血清肿瘤标志物、免疫功能的影响。方法:将120例晚期NSCLC患者采用随机数字表法分为观察组和对照组各60例。对照组患者采用化疗治疗,观察组患者采用化疗联合华蟾素片治疗。比较两组患者治疗前后各中医证候评分、肺癌生命质量量表EORTCQLQ-C30评分、中位生存时间及血清肿瘤标志物与免疫功能指标水平。结果:两组患者中医证候评分、EORTCQLQ-C30评分均较治疗前改善,且观察组改善更明显,差异均有统计学意义(P<0.05);观察组患者疗效指数高于对照组(P<0.05);观察组生存时间长于对照组(P<0.05);治疗后,观察组患者癌胚抗原(carcinoembryonic antigen,CEA)、细胞角蛋白19片段21-1(CYFRA21-1)、血管内皮生长因子(vascular endothelial growth factor,VEGF)等肿瘤标志物较治疗前降低,且低于对照组,差异均具有统计学意义(P<0.05);观察组NK、CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)较治疗前及对照组治疗后上升,差异均有统计学意义(P<0.05);对照组治疗后NK、CD3^(+),CD4^(+)和CD4^(+)/CD8^(+)较治疗前下降,差异有统计学意义(P<0.05)。结论:华蟾素可改善晚期NSCLC患者中医证候,降低血清肿瘤标志物水平及增强免疫功能,延长患者中位生存期,提高患者生存质量。Objective:To investigate the effects of cinobufacin on the improvement of syndromes,serum tumor markers and immune function in advanced non-small cell lung cancer(NSCLC)patients.Methods:All 120 patients with advanced NSCLC were divided into 60 cases each in the observation group and the control group using the random number table method.The patients in the control group were treated with chemotherapy,and the patients in the observation group were treated with chemotherapy combined with cinobufacin tablet.To compare the TCM syndrome scores,EORTCQLQ-C30 scores and median survival time of the two groups before and after treatment;to compare the levels of serum tumor markers and immune function indexes of the two groups before and after treatment.Results:The scores of each of the TCM syndromes and EORTCQLQ-C30 scores of patients of the two groups were improved compared with those before treatment,and the patients in the observation group improved better than those in the control group,and the differences were all statistically significant(P<0.05).Therapeutic index of patients in the observation group was higher than that of the control group(P<0.05).The median survival time of the observation group was longer than that of the control group(P<0.05).After treatment,tumor markers such as(carcinoembryonic antigen,CEA),cytokeratin 19 fragment 21-1(CYFRA21-1),and vascular endothelial growth factor(VEGF)were lower in the observation group compared with the pre-treatment period,and the observation group was lower than the control group,and the differences were all statistically significant(P<0.05).After treatment,NK,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)increased in the observation group compared with the control group and before treatment,and the differences were all statistically significant(P<0.05);NK,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)decreased in the control group compared with the pre-treatment period,and the differences were statistically significant(P<0.05).Conclusion:Treatment of advanced NSCLC patients with cinobufacin

关 键 词：非小细胞肺癌 中医证候 免疫功能 华蟾素 

分 类 号：R734[医药卫生—肿瘤]